Department of Otolaryngology, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning, China.
Department of Oncology, The General Hospital of Northern Theater Command, Shenyang, Liaoning, China.
Cell Cycle. 2020 May;19(9):1012-1021. doi: 10.1080/15384101.2020.1743910. Epub 2020 Apr 1.
Numerous researches show that MicroRNAs (miRNAs) participate in tumorigenesis, progression, recurrence and drug resistance of malignant tumors, including laryngocarcinoma. miR-552 works as an oncogene in both colorectal cancer and liver cancer. However, the potential role of miR-552 in laryngocarcinoma is unknown. Herein, we for first found that miR-552 expression was upregulated in laryngocarcinoma tissues compared with their normal controls. Moreover, miR-552 expression was also increasing in the laryngocarcinoma cells. miR-552 interference inhibited the proliferation and metastasis of laryngocarcinoma cells and . Mechanically, bioinformatics and luciferase reporter analysis identified p53 as a direct target of miR-552. miR-552 knockdown upregulated the p53 mRNA and protein expression in laryngocarcinoma cells. miR-552 expression was negatively associated with p53 expression in laryngocarcinoma tissues. More importantly, the p53 siRNA or p53 overexpression virus abrogated the discrepancy of growth and metastasis capacity between miR-552 interference laryngocarcinoma cells and control cells.
大量研究表明,MicroRNAs(miRNAs)参与了包括喉癌在内的恶性肿瘤的发生、发展、复发和耐药。miR-552 在结直肠癌和肝癌中作为癌基因发挥作用。然而,miR-552 在喉癌中的潜在作用尚不清楚。在此,我们首次发现 miR-552 在喉癌组织中的表达高于其正常对照。此外,miR-552 的表达也在喉癌细胞中增加。miR-552 干扰抑制了喉癌细胞的增殖和转移。并且,生物信息学和荧光素酶报告分析表明 p53 是 miR-552 的直接靶标。miR-552 下调抑制了喉癌细胞中 p53 mRNA 和蛋白的表达。miR-552 在喉癌组织中的表达与 p53 的表达呈负相关。更重要的是,p53 siRNA 或 p53 过表达病毒消除了 miR-552 干扰喉癌细胞与对照细胞之间生长和转移能力的差异。